Paper Details

  1. Home
  2. Paper Details

A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents.

Author: BaldwinR W, ByersV S, LevinA S, MalvinoA, RobinsR A, WaitesL

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Trichosanthin, a ribosomal inhibitory protein, was added to the antiretroviral treatment regimen of 93 HIV-infected patients. The addition of trichosanthin resulted in a significant increase in CD4+ cell levels, with a median increase of 1.2 cells/mm3/month. This suggests that trichosanthin may be a promising addition to HIV treatment.
Paper Details　
Original Abstract of the Article :
Patients infected with HIV, including those with AIDS-related complex and AIDS, and failing treatment with antiretroviral agents such as zidovudine, have been evaluated following addition of trichosanthin to the antiretroviral agent regimen. This ribosomal inhibitory protein is specifically cytotoxi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/aid.1994.10.413

データ提供：米国国立医学図書館（NLM）

A New Approach to HIV Treatment: Combining Trichosanthin with Zidovudine

HIV treatment research is constantly seeking new ways to combat the virus and improve the quality of life for patients. This study explores the potential of adding trichosanthin to the existing antiretroviral regimen for patients with HIV who have become resistant to zidovudine. Trichosanthin is a ribosomal inhibitory protein that specifically targets HIV-infected cells, offering a new avenue for treating HIV.

Boosting Immune Response: A Promising Combination

The study demonstrates that adding trichosanthin to zidovudine can significantly increase CD4+ cell levels in patients with HIV. The results show a promising combination of antiretroviral therapy and targeted cell inhibition, offering a potential for improved immune response and disease management.

Navigating HIV Treatment: Exploring New Horizons

This research offers a ray of hope for patients with HIV who have become resistant to existing treatments. It suggests that adding trichosanthin to the antiretroviral regimen may offer a viable option for boosting immune response and improving disease management. It's like discovering a new oasis in the vast desert of HIV treatment research, offering a path toward more effective and personalized therapies.

Dr.Camel's Conclusion

HIV treatment is a complex and evolving field, and this study highlights the potential of trichosanthin as a valuable addition to the antiretroviral arsenal. The research suggests that combining trichosanthin with zidovudine may offer a promising avenue for boosting immune response and improving disease management. It's like finding a hidden spring of hope in the desert of HIV treatment, offering a path toward more effective and personalized therapies.

Date :
  1. Date Completed 1994-09-29
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

7915124

DOI: Digital Object Identifier

10.1089/aid.1994.10.413

Related Literature

Article Analysis
・Side Effects of zidovudine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.